Aequus Pharmaceuticals Inc says it will maintain commercial relationship with Sandoz into 2022
Aequus Pharmaceuticals says it will maintain commercial relationship with Sandoz into 2022 There is potential to extend the current partnership beyond February 2022 and expand to include additional products beyond Vistitan and Tacrolimus IR Aequus is a growing specialty pharmaceutical company focused on developing and commercializing high-quality, differentiated products Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) (FRA:AEQ) will maintain its current commercial relationship pertaining to the Vistitan glaucoma drug, with Sandoz into 2022. As a specialty pharmaceutical c...